MX2013002055A - Variantes anti-enlace de albumina de suero mejodas. - Google Patents

Variantes anti-enlace de albumina de suero mejodas.

Info

Publication number
MX2013002055A
MX2013002055A MX2013002055A MX2013002055A MX2013002055A MX 2013002055 A MX2013002055 A MX 2013002055A MX 2013002055 A MX2013002055 A MX 2013002055A MX 2013002055 A MX2013002055 A MX 2013002055A MX 2013002055 A MX2013002055 A MX 2013002055A
Authority
MX
Mexico
Prior art keywords
serum albumin
albumin binding
improved anti
binding variants
variants
Prior art date
Application number
MX2013002055A
Other languages
English (en)
Inventor
Carolyn Enever
Haiqun Liu
Elena De Angelis
Oliver Schon
Malgorzata Pupecka-Swider
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of MX2013002055A publication Critical patent/MX2013002055A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)

Abstract

La invención se refiere a variantes mejoradas del único dominio variable de inmunoglobulina anti-albúmina de suero DOM7h-14-10, así como a ligandos y conjugados de fármacos que comprenden estas variantes, composiciones, ácidos nucleicos, vectores y huéspedes.
MX2013002055A 2010-08-20 2011-08-12 Variantes anti-enlace de albumina de suero mejodas. MX2013002055A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37532810P 2010-08-20 2010-08-20
PCT/EP2011/064000 WO2012022703A2 (en) 2010-08-20 2011-08-12 Improved anti-serum albumin binding variants

Publications (1)

Publication Number Publication Date
MX2013002055A true MX2013002055A (es) 2013-07-22

Family

ID=44582955

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013002055A MX2013002055A (es) 2010-08-20 2011-08-12 Variantes anti-enlace de albumina de suero mejodas.

Country Status (12)

Country Link
US (1) US20130230519A1 (es)
EP (1) EP2606065A2 (es)
JP (2) JP2013537421A (es)
KR (1) KR20130055663A (es)
CN (1) CN103282381A (es)
AU (1) AU2011290797A1 (es)
BR (1) BR112013003899A2 (es)
CA (1) CA2808683A1 (es)
EA (1) EA201390116A1 (es)
MX (1) MX2013002055A (es)
SG (1) SG188204A1 (es)
WO (1) WO2012022703A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA45051A (fr) 2016-05-18 2019-03-27 Modernatx Inc Polynucléotides codant la relaxine
BR112019011189A2 (pt) * 2016-12-07 2019-10-08 Ablynx Nv domínios variáveis únicos de imunoglobulina que se ligam à albumina sérica melhorada
IL305912A (en) 2017-01-17 2023-11-01 Ablynx Nv Improved serum albumin binding agents
WO2018134235A1 (en) 2017-01-17 2018-07-26 Ablynx Nv Improved serum albumin binders
GB201818460D0 (en) * 2018-11-13 2018-12-26 Crescendo Biologics Ltd Single domain antibodies that bind human serum albumin
EP3927740A4 (en) * 2019-02-22 2023-03-01 Anwita Biosciences, Inc. ALBUMIN-BINDING ANTIBODIES AND USE THEREOF
WO2024170756A1 (en) 2023-02-17 2024-08-22 Ablynx N.V. Polypeptides binding to the neonatal fc receptor

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
DK1517921T3 (da) 2002-06-28 2006-10-09 Domantis Ltd Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
DE602005023291D1 (de) 2004-03-24 2010-10-14 Domantis Ltd Universelles signalpeptid gas1
MXPA06014031A (es) 2004-06-01 2007-10-08 Domantis Ltd Anticuerpos de fusion biespecificos con vida media de serica mejorada.
BRPI0518761A2 (pt) 2004-12-02 2008-12-09 Domantis Ltd fusço de droga, conjugado de droga, Ácido nucleico recombinante, construÇço de Ácido nucleico, cÉlula hospedeira, mÉtodo para produzir uma fusço de droga, composiÇço farmacÊutica, droga, mÉtodo de tratamento e/ou prevenÇço de uma condiÇço em um paciente, mÉtodo de retardo ou prevenÇço de progressço de doenÇa, e, mÉtodo para diminuir a absorÇço de alimentos por um paciente
GB0521621D0 (en) 2005-10-24 2005-11-30 Domantis Ltd Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
TW200804425A (en) * 2005-12-06 2008-01-16 Domantis Ltd Ligands that have binding specificity for EGFR and/or VEGF and methods of use therefor
US20100047171A1 (en) 2006-01-24 2010-02-25 Roland Beckmann Fusion Proteins That Contain Natural Junctions
KR20100018040A (ko) * 2007-06-06 2010-02-16 도만티스 리미티드 프로테아제 내성 폴리펩티드를 선택하는 방법
GB0724331D0 (en) 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
TW200944231A (en) 2007-11-30 2009-11-01 Glaxo Group Ltd Antigen-binding constructs
AU2009231439A1 (en) * 2008-03-31 2009-10-08 Glaxo Group Limited Drug fusions and conjugates
ES2688621T3 (es) * 2008-12-05 2018-11-05 Glaxo Group Limited Métodos para seleccionar polipéptidos resistentes a proteasa
WO2010081787A1 (en) 2009-01-14 2010-07-22 Domantis Limited IMPROVED TNFα ANTAGONISM, PROPHYLAXIS & THERAPY WITH REDUCED ORGAN NECROSIS

Also Published As

Publication number Publication date
EA201390116A1 (ru) 2013-09-30
WO2012022703A3 (en) 2012-04-26
US20130230519A1 (en) 2013-09-05
JP2016027801A (ja) 2016-02-25
SG188204A1 (en) 2013-04-30
BR112013003899A2 (pt) 2016-06-07
WO2012022703A2 (en) 2012-02-23
CN103282381A (zh) 2013-09-04
CA2808683A1 (en) 2012-02-23
EP2606065A2 (en) 2013-06-26
AU2011290797A1 (en) 2013-04-11
JP2013537421A (ja) 2013-10-03
KR20130055663A (ko) 2013-05-28

Similar Documents

Publication Publication Date Title
MX2011008752A (es) Variantes de union a anti-albumina de suero mejoradas.
MX2012013406A (es) Variantes de union mejoradas anti-albumina serica.
MX2012000765A (es) Dominios variables sencillos de union de albumina anti-suero mejorados.
MX2011008749A (es) Variantes de union a anti-albumina de suero mejoradas.
CY1119567T1 (el) Θεραπευτικα πεπτιδια
WO2012072731A3 (en) Improved anti-serum albumin binding single variable domains
MX2013002055A (es) Variantes anti-enlace de albumina de suero mejodas.
WO2014083208A9 (en) Binding proteins comprising at least two repeat domains against her2
EA201401254A1 (ru) Самостабилизирующиеся линкерные конъюгаты
EA201390785A1 (ru) Антитела, обладающие низкой аффинностью к рецепторам гематоэнцефалического барьера, и их применения
UA106900C2 (uk) Агоністичний dr5-зв'язувальний поліпептид
AU2015370918A8 (en) Binding protein drug conjugates comprising anthracycline derivatives
NZ700891A (en) 4-1bb binding molecules
WO2012019024A3 (en) Her3-binding molecules and immunoconjugates thereof
WO2011086143A3 (en) Liver targeting domain antibodies
EA201290642A1 (ru) Соединения и способы
WO2011112566A3 (en) Basigin binding proteins
NZ700274A (en) Anti-pdgf-c antibodies
CA3036643C (en) Cmet monoclonal binding agents, drug conjugates thereof and uses thereof
WO2014044793A3 (en) Cd22-binding peptides
EP2569327A4 (en) EIF4E BINDING PEPTIDES
MX2016008478A (es) Nuevo anticuerpo anti adam17 y su uso en el tratamiento del cancer.
WO2012136792A3 (en) Cck compositions
CR20110473A (es) Variantes de union a anti-albúmina de suero mejoradas.
NZ626296A (en) Compositions and methods for antibodies targeting factor p

Legal Events

Date Code Title Description
FA Abandonment or withdrawal